View Document Preview and Link Document Date: 2014-11-17 10:17:04 Open Document File Size: 178,61 KB Share Result on Facebook
City NEWTON / / Company Allena Pharmaceuticals Inc. / Allena Pharmaceuticals Allena Pharmaceuticals Inc. / Allena Pharmaceuticals / / Event FDA Phase / / Facility Lurie Children's Hospital of Chicago / / IndustryTerm biopharmaceutical / chronic management / / MedicalCondition hyperoxaluria / serious metabolic disorder / primary hyperoxaluria / chronic kidney disease / secondary hyperoxaluria / nephrocalcinosis / Hyperoxaluria Hyperoxaluria / kidney stones / Kidney Diseases / nephrolithiasis / chronic management / orphan diseases / hereditary enzyme deficiency / clinically meaningful hyperoxaluria / / Organization Lurie Children's Hospital of Chicago / Feinberg School of Medicine / American Society of Nephrology Kidney Week / American Society of Nephrology / Northwestern University / / Person Craig B. Langman / / Position Professor of Kidney Diseases / head / Kidney Diseases / / Product ALLN-177 / / ProvinceOrState Massachusetts / / URL www.allenapharma.com / / SocialTag 
Allena Pharmaceuticals Presents Phase 1 Data on ALLN-177 at American Society of Nephrology Kidney Week 2014 NEWTON, Mass. – Nov. 17, 2014 – Allena Pharmaceuticals, Inc., a specialty biopharmaceutical company focused